Monday, August 17, 2020, 5:00 PM – 6:00 PM ET

Recent Advances in Medical Oncology: ER-Positive Breast Cancer

Join us on Monday, August 17 for the live webinar
5:00 PM – 6:00 PM ET
1 AMA PRA Category 1 CreditTM

Complimentary Registration
A link to the event will be provided after registration via an email confirmation.

A full library of presentation slides will also be made available for those who participate in this live webinar.


Virginia Kaklamani, MD, DSc
Professor of Medicine
Ruth McLean Bowman Bowers Chair in Breast Cancer Research and Treatment
AB Alexander Distinguished Chair in Oncology
Associate Director for Clinical Research
Leader of the Breast Cancer Program
UT Health San Antonio
The University of Texas
MD Anderson Cancer Center
San Antonio, Texas

Sara M Tolaney, MD, MPH
Associate Director
Susan F Smith Center for Women’s Cancers
Director of Clinical Trials, Breast Oncology
Director of Breast Immunotherapy Clinical Research
Senior Physician
Breast Oncology Program
Dana-Farber Cancer Institute
Assistant Professor of Medicine
Harvard Medical School
Boston, Massachusetts


Neil Love, MD
Research To Practice
Miami, Florida

Not an official event of ASCO20 Virtual. Not sponsored, endorsed, or accredited by ASCO, CancerLinQ, or Conquer Cancer.

This activity is supported by educational grants from AbbVie Inc, AstraZeneca Pharmaceuticals LP, Celgene Corporation, Daiichi Sankyo Inc, Genentech, a member of the Roche Group, Merck, Puma Biotechnology Inc and Seattle Genetics.

Part 1: Clinical Decision-Making for Patients with ER-Positive Localized Breast Cancer (BC)

  • Effects of patient age, tumor size/grade and other clinicopathologic factors on the decision to consult a genomic assay in the adjuvant setting for patients with ER-positive localized BC
  • Major clinical findings from the Phase III TAILORx intermediate-risk cohort; implications for adjuvant treatment for pre- and postmenopausal patients with localized BC
  • Biologic rationale for the evaluation of CDK4/6 inhibitors in localized ER-positive, HER2-negative BC
  • Design of, entry criteria for and similarities and differences between ongoing randomized Phase III trials exploring the potential role of adjuvant CDK4/6 inhibition in combination with endocrine therapy
  • Early findings from and potential clinical implications of the Phase III trials evaluating the addition of abemaciclib or palbociclib to standard adjuvant endocrine therapy in patients with HR-positive, HER2-negative early BC

Part 2: Selection and Sequence of Therapy for ER-Positive, HER2-Negative Metastatic BC (mBC)

  • Clinical factors affecting the use and selection of CDK4/6 inhibitors with endocrine therapy as first-line treatment for ER-positive mBC (eg, prior endocrine therapy, symptomatology, performance status, disease-free interval, sites of metastases)
  • Long-term follow-up data, including overall survival findings, with CDK4/6 inhibitors for premenopausal and postmenopausal patients; current clinical role
  • Current clinical role of alpelisib/fulvestrant for patients with a PIK3CA mutation after disease progression on first-line endocrine therapy and Phase III clinical data supporting the approval of this combination
  • Adverse event profiles associated with CDK4/6 inhibitors and alpelisib in patients with ER-positive mBC and optimal strategies to manage toxicities in patients receiving these agents
  • Ongoing investigation of other novel agents and strategies in patients with ER-positive mBC (eg, venetoclax, ipatasertib, capivasertib)

Target Audience
This program is intended for medical oncologists, hematology-oncology fellows and other allied healthcare professionals involved in the treatment of breast cancer.

Learning Objectives

  • Develop an optimal approach to adjuvant therapy for patients with ER-positive breast cancer (BC), considering the implications of patient age, tumor size/grade and other clinicopathologic factors on the treatment decision.
  • Consider published data to guide the use of biomarkers and genomic classifiers in assessing risk and customizing therapy for patients with hormone receptor-positive BC in the adjuvant setting.
  • Understand the biologic rationale for and available data with CDK4/6 inhibitors in localized ER-positive, HER2-negative BC, and assess the potential future role of these agents in the treatment of patients in this setting.
  • Develop an evidence-based algorithm for the treatment of advanced hormone receptor-positive pre- and postmenopausal BC, including endocrine, biologic and chemotherapeutic agents.
  • Recall the FDA indications for the commercially available CDK4/6 inhibitors, and discern how these agents can be optimally employed in the nonresearch care of patients with ER-positive metastatic BC.
  • Appraise available research data and clinical investigators’ perspectives to formulate appropriate clinical recommendations for patients who experience disease progression on CDK4/6 inhibitors in combination with hormonal therapy.
  • Recognize the approval of and published efficacy and safety data with the PI3 kinase inhibitor alpelisib in combination with fulvestrant for patients with metastatic HER2-negative BC harboring a PIK3CA mutation, and consider the diagnostic and therapeutic implications of these findings on nonresearch care.
  • Develop an understanding of available data with and potential clinical roles of other investigational agents and strategies to facilitate referral for clinical trial opportunities or prepare for the future availability of these approaches.

CME Credit Form
CME and ABIM MOC credit form links will be emailed to each participant within 5 days of the activity.

Accreditation Statement
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation Statement
Research To Practice designates this live activity for a maximum of 1 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

American Board of Internal Medicine (ABIM) — Maintenance of Certification (MOC)
Successful completion of this CME activity, which includes participation in the evaluation component and a short post-test, enables the participant to earn up to 1 Medical Knowledge MOC point in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Please note, this program has been specifically designed for the following ABIM specialty: medical oncology.

Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at for more information. For those clinicians wishing to receive ABIM MOC credit for attending, you will receive an email after the event with instructions.

Content Validation and Disclosures
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess conflicts of interest with faculty, planners and managers of CME activities. Conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

FACULTY — The following faculty (and their spouses/partners) reported relevant conflicts of interest, which have been resolved through a conflict of interest resolution process:

Dr KaklamaniConsulting Agreements: Amgen Inc, AstraZeneca Pharmaceuticals LP, Athenex, Celldex Therapeutics, Eisai Inc, Immunomedics Inc, Puma Biotechnology Inc; Contracted Research: Eisai Inc; Data and Safety Monitoring Board/Committee: Bristol-Myers Squibb Company; Speakers Bureau: AstraZeneca Pharmaceuticals LP, Celgene Corporation, Daiichi Sankyo Inc, Eisai Inc, Genentech, a member of the Roche Group, Genomic Health Inc, Novartis, Pfizer Inc, Puma Biotechnology Inc. Dr TolaneyConsulting Agreements: AbbVie Inc, AstraZeneca Pharmaceuticals LP, Athenex, Bristol-Myers Squibb Company, Celldex Therapeutics, Eisai Inc, G1 Therapeutics, Genentech, a member of the Roche Group, Immunomedics Inc, Lilly, Merck, NanoString Technologies, Nektar, Novartis, Odonate Therapeutics, OncoPep, Paxman, Pfizer Inc, Puma Biotechnology Inc, Sanofi Genzyme, Seattle Genetics, Silverback Therapeutics; Contracted Research: AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, Cyclacel Pharmaceuticals Inc, Eisai Inc, Exelixis Inc, Genentech, a member of the Roche Group, Immunomedics Inc, Lilly, Merck, NanoString Technologies, Nektar, Novartis, Odonate Therapeutics, Pfizer Inc, Sanofi Genzyme, Seattle Genetics.

MODERATORDr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following commercial interests: AbbVie Inc, Acerta Pharma — A member of the AstraZeneca Group, Adaptive Biotechnologies Corporation, Agendia Inc, Agios Pharmaceuticals Inc, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Biodesix Inc, bioTheranostics Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Boston Biomedical Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Daiichi Sankyo Inc, Dendreon Pharmaceuticals Inc, Eisai Inc, EMD Serono Inc, Exelixis Inc, Foundation Medicine, Genentech, a member of the Roche Group, Genmab, Genomic Health Inc, Gilead Sciences Inc, GlaxoSmithKline, Grail Inc, Guardant Health, Halozyme Inc, Helsinn Healthcare SA, ImmunoGen Inc, Incyte Corporation, Infinity Pharmaceuticals Inc, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Kite, A Gilead Company, Lexicon Pharmaceuticals Inc, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, Merrimack Pharmaceuticals Inc, Myriad Genetic Laboratories Inc, Natera Inc, Novartis, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Prometheus Laboratories Inc, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sandoz Inc, a Novartis Division, Sanofi Genzyme, Seattle Genetics, Sirtex Medical Ltd, Spectrum Pharmaceuticals Inc, Taiho Oncology Inc, Takeda Oncology, Tesaro, A GSK Company, Teva Oncology, Tokai Pharmaceuticals Inc, Tolero Pharmaceuticals and Verastem Inc.

— Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.

This activity is supported by educational grants from AbbVie Inc, AstraZeneca Pharmaceuticals LP, Celgene Corporation, Daiichi Sankyo Inc, Genentech, a member of the Roche Group, Merck, Puma Biotechnology Inc and Seattle Genetics.